Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
about
The dopamine hypothesis of schizophrenia: version III--the final common pathwayThe Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's DiseaseEvidence for the use of pimavanserin in the treatment of Parkinson's disease psychosisUpdate on the treatment of Parkinson’s disease psychosis: role of pimavanserinPharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.Minds on replay: musical hallucinations and their relationship to neurological disease.Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ mice: comparison to dopamine receptor agonists.Adenosine A(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's DiseaseMusical hallucinations treated with acetylcholinesterase inhibitors.Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research.Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?Cortical and Striatal Reward Processing in Parkinson's Disease Psychosis.Correlation of sleep disturbance and cognitive impairment in patients with Parkinson's disease.Palliative care in Parkinson's disease: role of cognitive behavior therapy.Neuromelanin magnetic resonance imaging reveals increased dopaminergic neuron activity in the substantia nigra of patients with schizophrenia.Psychiatric side effects of non-psychiatric drugs.Profile and variables related to antipsychotic consumption according to dementia subtypes.Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.Parkinson's psychosis.Inhibition of Apoptosis and Efficacy of Pan Caspase Inhibitor, Q-VD-OPh, in Models of Human Disease.The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study.Advances in the treatment of visual hallucinations in neurodegenerative diseases.Current strategies in the treatment of Parkinson's disease and a personalized approach to management.Agitation and psychosis associated with dementia with lewy bodies exacerbated by modafinil use.Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.Clinicopathological correlates of behavioral and psychological symptoms of dementia.Paradoxical and bidirectional drug effects.Neural and behavioral substrates of subtypes of Parkinson's disease.Psychiatric issues in cognitive impairment.Visual hallucinations in Parkinson's disease: theoretical models.Anticholinergic burden in Parkinson's disease inpatients.Targeting voltage-gated calcium channels in neurological and psychiatric diseases.Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations.Worldwide Differences in Regulations of Clozapine Use.Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.Current Understanding of Psychosis in Parkinson's Disease.Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states.Non-motor features of Parkinson disease.Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients.
P2860
Q22242827-D8F6080C-EEF2-48CB-97DC-3C2C8B78C3B8Q26738456-24FCE97C-0A10-4835-8305-EE8AA43C3AE1Q28074468-082853FC-4210-4806-A0F7-C8659A222E7DQ29048641-B09806C3-87F4-4200-AAF4-440DE16D3061Q30244035-DCF1D619-AA9E-43C0-BFAD-724273128682Q30380073-8212127C-E858-4298-AEAD-DBAD312F726CQ30459631-F5C02BDD-ECFD-439B-AF86-3B8C33E48408Q30472044-7BDB1AB2-D24C-4E23-851B-84F6098EC014Q30566553-EEAD483B-9F12-4EE2-91FF-9089BD9F0482Q30582343-7B94094B-6477-4689-A4DE-5514A65B1848Q33353554-3D05E4EE-0B4A-4411-8490-033016EFE82FQ33593735-5BCA0C07-EFDE-41A0-AD88-4E7541DFC679Q33734416-69CC0F9F-E5D3-4F9F-817F-3A40C8EC0021Q33915603-E1B10EC8-DB9A-43B2-AC9E-F944636E0E9EQ34028030-C799D2A6-0B5B-4E59-8374-BA0511B48729Q34138808-B268EB3B-1BDE-425B-BAA1-8B49CF0EE2FAQ34158495-F10E0B9C-42BF-402B-A5AF-1CE86AAA7666Q34361389-3B9D18BD-26D6-41F2-AD0E-0CF3BF0A9591Q34610632-3F65E619-8E56-42ED-A542-B4210B9F91A5Q35390301-E874DEE0-29C2-48F0-A67D-3AF76AA7C9C4Q35653501-72E5F621-5AE6-49B7-B643-38DF9F26B586Q37029454-D4EDB1DD-7688-413E-881C-DF56D333F5D8Q37642000-F926A097-6F03-4E1F-9079-3EF3FD958848Q37734694-7B9B51A7-2A11-4C77-9D06-DA3F774EE54CQ37782115-7DAFE993-F488-4A7D-80E9-7F432BEEF503Q37860194-1EDEA6AD-C294-4DCC-9A12-C611D55416FBQ37978338-DC494E4D-9F19-47DB-A808-CACA8E7232E3Q38176606-DE6D746D-308F-465D-A373-B4F77FD8643EQ38206498-63794460-A434-42AE-9D55-6D8B2030D45BQ38243013-0F19EFEE-3A5E-4FC9-B805-306D0A9A8404Q38406475-EC4A8B96-8C93-4161-848A-FD666DFD9760Q38626606-F9BC2B46-8B87-44F5-955F-1AD5BEB1022FQ38690185-A53D84CB-A30C-44E9-8DAB-A05E8DB688B7Q38736547-D32D845B-E4B2-4EFB-8109-A8459BF97DBFQ38894971-2175BC0E-BC3D-4CC9-BA6E-29BA3C69AB18Q38954642-84C9A8F3-BFA5-4D8C-873B-76CAC19154A1Q39004255-58163EE9-11AA-4222-80A2-2C4915209A5CQ39125374-E9B83C93-1D2C-4E9A-9C31-720F907E0EB6Q39358549-6EFEFB14-7584-426A-92E8-9AFE4FE50295Q39516476-0FEE10CC-9716-4F5B-A24F-D284F014BE00
P2860
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
@ast
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
@en
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
@nl
type
label
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
@ast
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
@en
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
@nl
altLabel
Pathophysiology and Treatment of Psychosis in Parkinson’s Disease
@en
prefLabel
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
@ast
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
@en
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
@nl
P2860
P921
P1433
P1476
Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
@en
P2860
P304
P356
10.2165/00002512-200825080-00004
P4011
ee7b920ce65092b583330ede6983e6baef566059
P577
2008-01-01T00:00:00Z
P5875
P6179
1022747795